The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd)
Active ingredients
palopegteriparatide
Date of review outcome
Lapse date
Type
Priority review
Indication
A prodrug providing sustained release of parathyroid hormone (PTH(1-34)), is a PTH replacement therapy indicated for the treatment of hypoparathyroidism in adults
Therapeutic area
Endocrinology